Thursday, March 28, 2024
Home Tags Positive

Tag: positive

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial...

0
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy- NEXI-001 is well tolerated with...

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in...

0
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients with recurrent/metastatic head and neck cancerHOOKIPA is preparing...

Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Resp…...

0
8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD...

Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial …...

0
After a Single Administration of JK07, Patients in All Dose Cohorts Showed Improvement in Ejection Fraction (EF) Through Day 90 JK07 was Generally Safe...

Positive Interim Data of BellaSeno’s Clinical Trial with Resorbable Breast and...

0
Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno's resorbable implants are safe, well tolerated and lead to natural...

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1,...

0
RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve...

SKF First-quarter report 2023: Strong organic sales and positive margin trend...

0
GOTHENBURG, Sweden, April 27, 2023 /PRNewswire/ -- Rickard Gustafson, President and CEO:"Review of the first quarterI'm pleased to report a solid quarter with strong...

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 C… –...

0
Multiple Myeloma92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million...

Enento Group’s Interim Report 1.1. – 31.3.2023: Positive start to the...

0
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 24 APRIL 2023 AT 12.15 P.M. EESTEnento Group's Interim Report 1.1. – 31.3.2023: Positive start to the...

Pharma Two B to Present Additional Positive Results from P2B001 Phase...

0
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole,...

Press Realease

Business News

Cricket

Weather News

Lifestyle

World News

UK / USA News

Local News